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Background. In an eﬀort to group mental disorders on the basis of etiology, ﬁve clusters have been proposed. Here
we consider the validity of the cluster comprising selected psychotic and related disorders.
Method. A group of diagnostic entities classiﬁed under schizophrenia and other psychotic disorders in DSM-IV-TR
were assigned to this cluster and the bordering disorders, bipolar (BD) and schizotypal personality disorders (SPD),
were included. We then reviewed the literature in relation to 11 validating criteria proposed by the DSM-V Task
Force Study Group.
Results. Relevant comparisons on the 11 spectrum criteria are rare for the included disorders except for schizo-
phrenia and the two border conditions, BD and SPD. The core psychosis group is congruent at the level of shared
psychotic psychopathology and response to antipsychotic medication. BD and SPD are exceptions in that psychosis is
not typical in BD-II disorder and frank psychosis is excluded in SPD. There is modest similarity between schizo-
phrenia and BD relating to risk factors, neural substrates, cognition and endophenotypes, but key diﬀerences are
noted. There is greater support for a spectrum relationship of SPD and schizophrenia. Antecedent temperament, an
important validator for other groupings, has received little empirical study in the various psychotic disorders.
Conclusions. The DSM-IV-TR grouping of psychotic disorders is supported by tradition and shared psycho-
pathology, but few data exist across these diagnoses relating to the 11 spectrum criteria. The case for including BD
is modest, and the relationship of BD to other mood disorders is addressed elsewhere. Evidence is stronger for
inclusion of SPD, but the relationship with other personality disorders along the 11 criteria is not addressed and the
absence of psychosis presents a conceptual problem. There are no data along the 11 spectrum criteria that are decisive
for a cluster based on etiology, and inclusion of BD and SPD is questionable.
Received 22 May 2008 ; Revised 7 April 2009 ; Accepted 12 May 2009 ; First published online 1 October 2009
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Introduction
DSM-IV is organized into 16 chapters, and ICD-10
manages a similar number of disorders within 10
chapters. The planning for DSM-V and ICD-11 is in
progress. The time is propitious for a fresh look at the
organization of disorders into groups or clusters. A
new organization could reﬂect both the risk factors and
the clinical manifestations of disorders (Andrews et al.
2009a). Five clusters of disorders are proposed: Neuro-
cognitive (Sachdev et al. 2009), Neurodevelopmental
(Andrews et al. 2009b), Psychoses, Emotional
(Goldberg et al. 2009b) and Externalizing (Krueger &
South, 2009).
Here we summarize the evidence for including two
boundary disorders in the psychosis cluster, schizo-
typal personality disorder (SPD) and bipolar disorder
(BD), applying 11 spectrum criteria recommended by
the DSM-V Study Group (Hyman et al. personal com-
munication, December 2007).
Shared genetic risk factors and familiality
Early family and twin studies show that familial risks
are partly shared among schizophrenia, other non-
aﬀective psychoses and SPD, and, to a lesser extent,
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BD and aﬀective psychoses (Kendler & Gardner,
1997). These ﬁndings are further corroborated by sev-
eral recent large population-based studies (Mortensen
et al. 2003 ; Laursen et al. 2005). Birmaher et al. (2009)
reported on 388 oﬀspring of 233 parents with BD. Of
the 52.1% with axis I disorders, most were mood and
anxiety disorders and none received diagnoses of
schizophrenia and related disorders. However, some
studies do show familial co-aggregation of BD and
schizophrenia (Bramon & Sham, 2001; Craddock &
Owen, 2005). Cardno et al. (2002) report common and
speciﬁc genetic contributions to liability for schizo-
phrenia and BD, and schizo-aﬀective disorder over-
lapped with schizophrenia and/or BD. In the most
deﬁnitive study, Lichtenstein et al. (2009) analyzed
data from over a million nuclear families including
more than 75 000 probands with schizophrenia or
BD in a national sample from the Sweden registry.
About 60% of the variance of each disease is based on
genetic eﬀects, and about half of the genetic eﬀect
is shared and about half is unique. Owen et al. (2007)
provide a model for the genetic deconstruction of
psychoses.
Until recently, the evidence for shared candidate
genes and chromosomal locations in schizophrenia
and BD from linkage and gene association research
was considered relatively robust. Meta-analyses sup-
ported this view (Badner & Gershon, 2002 ; Berrettini,
2003 ; Lewis et al. 2003 ; Segurado et al. 2003). However,
Sullivan (2007) noted that a meta-analysis produces
a high number of overlapping genes by chance,
and Segurado et al. (2003) did not ﬁnd overlap in
the highest ranking genes for each disorder. Recent
genome-wide association studies (GWAS) cast further
doubt on the likelihood that leading candidate genes
will be useful in testing validity of diagnostic classes
and instead suggest that the contribution of any single
gene is very small (Wellcome Trust Case Control
Consortium, 2007; Sklar et al. 2008).
A shared genetic liability for schizophrenia and BD
may be associated with psychopathology common
to both disorders (e.g. depression, reality distortion)
and may not be relevant for diﬀerential diagnosis.
Investigators have observed an ampliﬁed linkage sig-
nal in loci shared by the two disorders when they
focused on subgroups of families based on psychosis
or aﬀective symptoms (Potash et al. 2001 ; Hamshere
et al. 2005).
In summary, family, twin and genetic studies pro-
vide evidence for both shared and non-shared con-
tributions to schizophrenia and BD. However, speciﬁc
genes are not yet useful in validating diagnoses. The
relevance of genetic eﬀects to the question of grouping
BD and schizophrenia together depends on whether
the focus is on shared or unique genetic eﬀects.
Environmental risk factors and gene–environment
interactions
Several environmental factors have been associated
with schizophrenia, some of which are also associated
with BD. Substance misuse (Henquet et al. 2005, 2006),
prenatal factors, particularly preterm birth (Susser
et al. 1996 ; Brown et al. 2000 ; Clarke et al. 2006 ; Scott
et al. 2006 ; Laursen et al. 2007), negative life events and
childhood trauma (van Os et al. 1998 ; Hammersley
et al. 2003 ; Read et al. 2005) are reported to be linked
to both diagnostic classes. Schizophrenia and BD
psychotic episodes are also associated with urban-
icity, possibly reﬂecting a precipitant eﬀect of envir-
onmental risks in genetically vulnerable individuals
(Krabbendam & van Os, 2005 ; Kaymaz et al. 2006). BD
without positive psychotic symptoms, however, is
not correlated with urbanicity (Kaymaz et al. 2006).
Advanced paternal age and Toxoplasma gondii are as-
sociated with schizophrenia and not known to be risk
factors in BD (Laursen et al. 2007; Mortensen et al.
2007 ; Perrin et al. 2007 ; Torrey & Yolken, 2007 ; Torrey
et al. 2007 ; Yolken & Torrey, 2008).
These environmental risk factors are common to
many disorders and thus are not determinative of
cluster membership. Rather, they may contribute to
dimensions of psychopathology across diagnostic cat-
egories. Researchers are turning their attention to
understanding the complex ways in which nature in-
teracts with nurture to produce psychosis. This geno-
typerenvironmental interaction (GrE) approach
posits a causal role for synergistic co-participation,
where the eﬀect of one is conditional on the other
(Leboyer et al. 2008). GrE seems a particularly suit-
able approach for understanding the development of
psychosis across the diagnostic categories in DSM. The
psychosis phenotype is known to be associated with
environmentally mediated risks, yet people display
considerable heterogeneity in their response to those
environmental exposures (van Os et al. 2008).
Shared neural substrates
Many neuroimaging studies compare schizophrenia
to healthy controls (HC) but fewer examine diﬀerences
between BD and HC. Fewer still directly compare
schizophrenia and BD subjects and, of these, only a
subset speciﬁes whether psychosis is present in the BD
cases. Neural substrate ﬁndings are summarized in
Table 1.
Magnetic resonance imaging (MRI)
Structural anatomical abnormalities are reported
across the psychosis spectrum. Most commonly, gray
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matter reductions in multiple regions have been
identiﬁed in schizophrenia and BD patients, when
compared to HC. The magnitude of these eﬀects is
larger in schizophrenia but similar to BD in abnormal
topography. Meta-analyses document a 3–4% whole-
brain volume reduction in schizophrenic probands
compared to HC (see e.g. Woodruﬀ et al. 1995 ; Wright
et al. 2000 ; Steen et al. 2006 ; for a review, Harrison,
1999) that is not entirely consistent with the pattern of
volume loss in BD (Hoge et al. 1999). In both schizo-
phrenia and BD, volume reductions are most consist-
ently reported in cortical gray matter, particularly in
frontotemporal regions. Relatives of schizophrenic
probands and high-risk individuals also have signiﬁ-
cant, though smaller, volume reductions compared to
HC (Seidman et al. 1999; Lawrie et al. 2001; O’Driscoll
et al. 2001 ; Ho, 2007). Of note, there is a concomitant
increase in sulcal and ventricular cerebral spinal ﬂuid
in schizophrenic probands. Ventricular enlargement
also occurs in BD and may be more severe in patients
with multiple episodes (Hauser et al. 2000 ; Strakowski
et al. 2002), but long-term longitudinal studies (com-
parable to those in early schizophrenia) are lacking.
A meta-analysis suggests that right-side ventricular
enlargement is the most consistent ﬁnding in BD
(McDonald et al. 2004). The diﬃculty in relating im-
aging ﬁndings to the diagnostic grouping issue is illus-
trated by McIntosh et al. (2005), who report reduced
white matter density in the anterior limb of the inter-
nal capsule in both syndromes. However, unaﬀected
relatives did not have this reduction and a reduction in
frontal subgyral white matter was only observed in
cases with a family history of schizophrenia.
Longitudinal changes (mainly gray matter re-
ductions) early in schizophrenia have been repeatedly
demonstrated as early as 3 months after treatment (see
e.g. DeLisi et al. 1997 ; McCarley et al. 1999; Rapoport
et al. 1999 ; Lieberman et al. 2001 ; Ho et al. 2003 ; van
Haren et al. 2003 ; Theberge et al. 2007). Lieberman et al.
(2005) documented global gray matter reductions
early in schizophrenia. Early brain volume reduction
may stabilize in early adulthood (Woods, 1998) or later
(Mathalon et al. 2001), but most evidence suggests
progressive changes during the course of schizo-
phrenia (Arango et al. 2008; DeLisi, 2008 ; Lawrie et al.
2008 ; Hulsoﬀ Pol & Kahn, 2008 ; Wood et al. 2008). It is
not known whether progressive changes followed by
stabilization is the pattern for BD. Epiphenomena such
as substance abuse, therapeutic drugs and intense
smoking may contribute to these observations (see e.g.
Dorph-Petersen et al. 2005 ; Rais et al. 2008).
Subcortical striatal regions may be enlarged in BD
compared to HC (Strakowski et al. 2005) and in schizo-
aﬀective disorder (Getz et al. 2002). The available evi-
dence has found increased amygdala in BD and
reduced hippocampi in schizophrenia (Altshuler et al.
Table 1. Summary of neural substrate ﬁndings in schizophrenia (Sz), bipolar (BP) disorder and healthy normal volunteers (HNV)
Sz v. HNV
BP v. HNV
Cross Longitudinal Cross Sz v. BP
MRI ›GM+++ ›GM++ ›GM+ ›GM+ (Sz<BP)
›WM++ ›WM+
‹CSF+ ‹CSF++ ‹CSF+ ‹CSF+ (Sz>BP)
H-MRS ›NAA++ ›NAA+ None
‹Glu+
P-MRS ‹PDE+ ‹PME+ None
DTI ›FA++ Unclear None
PET receptors Unclear D2 receptors Unclear D2 receptors None
fMRI Network diﬀerences++ Network diﬀerences+ Two studies suggest network
diﬀerences
Post-mortem
ultrastructure
‹Neuronal density+ ›Neuronal density+ None
›Glial density+
Post-mortem gene
expression
›GABA markers++ ›GABA markers+ ›GABA markers+
both disorders
MRI, Magnetic resonance imaging ; H-MRS, proton magnetic resonance spectroscopy ; P-MRS, phosphorus magnetic
resonance spectroscopy ; DTI, diﬀusion tensor imaging ; PET, positron emission tomography ; fMRI, functional MRI ;
GM, gray matter ; WM, white matter ; CSF, cerebrospinal ﬂuid ; NAA, N-acetylaspartate ; Glu, glutamate ;
PDE, phosphodiesters ; FA, fractional anisotropy ; GABA, gamma-aminobutyric acid ; PME, phosphomonoesters.
›, Decreased ; ‹, increased ;+, some evidence ;++, some replications ;+++, repeatedly replicated ﬁnding.
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1998; Strakowski et al. 1999). One study has followed
ﬁrst-episode psychosis subjects with a baseline and
repeat MRI (1.5 years later). Both schizophrenia and
psychotic BD subjects had smaller left superior tem-
poral volumes than HC, but only schizophrenia sub-
jects had further volume reductions (McCarley et al.
1999). However, a recent report failed to document
gray or white matter diﬀerences between BD subjects
and non-ill controls (Scherk et al. 2008). Medications
may confound relationships between diagnostic co-
horts.
Direct comparisons between the ﬁrst-degree re-
latives (FDRs) of BD and schizophrenia subjects have
revealed prefrontal gray and white matter reductions
in schizophrenia relatives but not in BD relatives
(McIntosh et al. 2006). Hippocampal volumes were
reduced in the schizophrenia subjects but not in their
relatives. BD and their relatives had normal brain
volume indices (McDonald et al. 2006).
Although these studies highlight broad similarity in
the brain systems aﬀected in schizophrenia and BD
(i.e. frontotemporal), the data arguably provide the
most persuasive evidence for neuroanatomical dif-
ferences between schizophrenia and BD. Important
(and potentially opposite) eﬀects of antipsychotic
and mood-stabilizing agents cannot be excluded, but
the presence of disease-speciﬁc abnormalities in the
schizophrenia relatives, but not in the BD relatives,
strongly suggests that brain volume deﬁcits are not
entirely accounted for by a medication eﬀect in schizo-
phrenia. However, given evidence for neurotrophic
eﬀects of mood-stabilizing agents (Sassi et al. 2002) that
could increase gray matter volumes in BD subjects,
a complex contribution of psychotropic medications
(reduced cortical volumes and increased striatal vol-
umes with antipsychotics and increased cortical vol-
umes with mood stabilizers) must be considered in
relation to conclusions regarding disease-speciﬁc volu-
metric abnormalities.
Diﬀusion tensor imaging (DTI)
Many studies have examined white matter tract in-
tegrity with DTI in schizophrenia/HC comparisons.
There have been several reports of reduced white
matter integrity in schizophrenia in a variety of re-
gions (Gur et al. 2007). There are fewer reports
regarding BD and these are not consistent. Yurgelun-
Todd et al. (2007) report increased white matter integ-
rity, whereas Adler et al. (2004) report reduced white
matter integrity. No direct comparisons between di-
agnostic groups are currently available.
Magnetic resonance spectroscopy (MRS)
There is abundant evidence of neuronal dysfunction in
both schizophrenia and BD. BD is characterized by
reduced N-acetylaspartate (NAA), a marker of neu-
ronal viability (Yildiz-Yesiloglu & Ankerst, 2006).
However, as in the MRI literature, there are sugges-
tions of neuroprotective eﬀects of lithium, leading to
NAA elevations (Brambilla et al. 2005). Direct com-
parisons between the diagnostic groups are lacking.
Glutamatergic indices are increased in medication-
naive schizophrenia probands and those at high risk of
the disorder (Theberge et al. 2002 ; Tibbo et al. 2004 ;
Chang et al. 2007). Glutamate indices are also increased
in unmedicated BD (Dager et al. 2004). No study has
directly compared these metabolites between schizo-
phrenia and BD.
Positron emission tomography (PET)/single photon
emission computed tomography (SPECT)
neuroreceptor studies
A review of D2 densities in vivo and post-mortem in
schizophrenia is suggestive of increased D2 receptors
(Zakzanis & Hansen, 1998). BD with psychosis is also
associated with increased striatal D2 receptor density
comparable to medication-naive schizophrenia pro-
bands. This is not found in non-psychotic BD. These
studies suggest that psychosis, irrespective of schizo-
phrenia or mood disorder, is related to increased D2
receptor density. This is consistent with the clinical
evidence regarding the eﬃcacy of D2 blockade for
psychotic symptoms regardless of diagnosis. The sig-
niﬁcance of these pharmacological ﬁndings has been
explicated in a heuristic model linking excessive
dopamine to the development of reality distortion
symptoms through its role in reward-based behav-
ior, and the assignment of motivational signiﬁcance
to external stimuli (Kapur et al. 2005; van Os & Kapur,
in press). This model provides a means of linking
dopamine dysregulation with delusion and halluci-
nation through aberrant associations of salience, and
suggests that antipsychotic drugs may serve to ‘de-
tach’ an individual from both aberrant and normal
motivational salience. Receptor data are particularly
vulnerable to drug eﬀects. Reality distortion symp-
toms occur in many disorders outside the psychosis
cluster.
Functional MRI (fMRI)
Functional imaging studies highlight important dif-
ferences in the activation of frontostriatal networks
in schizophrenia and BD patients, depending on
task requirements. Working memory performance in
schizophrenia has been commonly associated with
hypoactivation of the dorsolateral prefrontal cortex
(DLPFC), although there is also evidence of hyper-
activation in anterior cingulate and frontal pole
regions (Glahn et al. 2005). Comparatively fewer
studies in BD nevertheless report similar patterns of
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hypofrontal activation during working memory task
performance (see Phillips & Vietta, 2007). Other stud-
ies using emotional stimuli have revealed a pattern
of increased subcortical striatal and limbic activation
alongside reduced prefrontal cortex activity in BD (see
Green et al. 2007). This pattern of activity is also evi-
dent in pediatric cases of BD (Dickstein et al. 2007 ;
Pavuluri et al. 2008). In schizophrenia, there is a con-
trasting pattern of decreased limbic activation and
hyperfrontality during emotion processing tasks (e.g.
Holt et al. 2006). Finally, use of a sentence completion
task to study neural correlates of inhibitory control
in medicated schizophrenia, BD and HC groups has
shown increased activation in the right insula in
schizophrenia, whereas BD had reduced activation
in this region (McIntosh et al. 2008). Conversely, BD
had increased activity in the left DLPFC, whereas
schizophrenia subjects had reduced activation in this
region. A model including activation of the ventral
striatum, middle temporal gyrus, DLPFC and right
insula correctly classiﬁed 92% of BD and 58% of
schizophrenia subjects. Thus, as in other imaging
areas, some data suggest similarity and other data
suggest important diﬀerences between schizophrenia
and BD.
Post-mortem
Post-mortem studies show both similarities and dif-
ferences between schizophrenia and BD. Similarities
focus mainly on reduced gamma-aminobutyric acid
(GABA)ergic indices in the anterior cingulate and
hippocampus. There have been several studies de-
scribing evidence of decreased glutamic acid de-
carboxylase (GAD67) mRNA levels in the limbic lobe
of both BD and schizophrenia (e.g. Akbarian &Huang,
2006 ; Benes et al. 2006). Reports from the Stanley
Neuropathology Consortium are somewhat consistent
with these ﬁndings. Evidence of reduced parvalbu-
min-containing cells in hippocampus layer CA2
(which represent GABAergic interneurons) was found
in a direct comparison of both schizophrenia and BD
tissue samples compared to HC (Knable et al. 2004).
BD and schizophrenia groups shared about 65%
of abnormalities in a variety of mRNA and pro-
tein markers related to developmental/synaptic and
GABAergic systems (Torrey et al. 2005).
Schizophrenia and BD are associated with conﬂict-
ing glial proﬁles. Schizophrenia shows increased neu-
ronal density and glial density in prefrontal regions
(Selemon et al. 1995) and decreased dendritic spines
(Glantz & Lewis, 2000) without neuronal loss or gliosis
(Harrison, 1999). This has been interpreted as reduction
of the neuropil, with increased neuronal packing in
cortical layers III to VI. In contrast to schizophrenia,
BD shows reduced glial and neuronal density coupled
with glial hypertrophy in these regions (Ongur et al.
1998 ; Rajkowska et al. 2001). These ﬁndings suggest
distinct neuropathological substrates in schizophrenia
and BD but the samples were small and the poten-
tial contribution of medications to these post-mortem
ﬁndings cannot be dismissed (Dorph-Petersen et al.
2005).
In summary, the neuroanatomy literature contains
compelling reports of diﬀerences between BD and
schizophrenia, but similarities are also observed.
There are few direct comparisons between the two
groups using MRI (Altshuler et al. 1998 ; McCarley
et al. 1999 ; Strakowski et al. 1999 ; McDonald et al. 2006;
McIntosh et al. 2006), which all report reduced brain
tissue volumes in schizophrenia. Because small eﬀects
are expected and the measurement variability with
most of these neuroimaging tools is large, concurrent
study of both disorders is essential.
Shared biomarkers
Several neurophysiological abnormalities are ob-
served in psychotic disorders before the onset of psy-
chosis, are reported to be stable over the course of the
illness, and are only mildly aﬀected by psychotic state
and medications. Recent data indicate that, in most
part, these neurophysiological deﬁcits are indepen-
dent of each other, and are observed in non-ill re-
latives of schizophrenia patients and in subjects with
schizotypal traits (Light & Braﬀ, 2001 ; Braﬀ et al. 2007;
Gur et al. 2007 ; Hong et al. 2007 ; Turetsky et al. 2007).
Many of the same endophenotypes are now being
studied in BD subjects and their FDRs (Hill et al. 2008;
Pearlson & Folley 2008; Thaker, 2008).
Smooth pursuit and saccadic eye movement
abnormalities
Schizophrenia patients with primary and enduring
negative symptoms have impairment in smooth pur-
suit eye initiation (Hong et al. 2003). Furthermore,
pursuit maintenance and, more speciﬁcally, predictive
pursuit response are abnormal in FDRs of schizo-
phrenia patients and probands, particularly those with
schizotypal symptoms (Holzman et al. 1974 ; Thaker
et al. 1998, 2003 ; Avila et al. 2006 ; Hong et al. 2008), and
are thought to mark psychosis liability (Hong et al.
2006). BD probands and their relatives also show
pursuit abnormality similar to the relatives of schizo-
phrenia probands (Rosenberg et al. 1997 ; Kathmann
et al. 2003).
In addition to the smooth pursuit eye movement
abnormalities, studies have observed abnormality
in saccadic inhibition (anti-saccades) and oculomotor
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delayed responses (which assess spatial workingmem-
ory) in schizophrenia probands and their relatives,
and also in personswith aﬀective disorders (see review
by Thaker, 2008).
Sensory gating (P50) deﬁcit
Schizophrenia and BD probands with a lifetime his-
tory of psychosis show muted inhibition as measured
by P50 responses to a paired click paradigm (Perry
et al. 2001 ; Sa´nchez-Morla et al. 2008). This deﬁcit is not
consistently aﬀected by medication status or clinical
state. BD without a history of psychosis is not as-
sociated with abnormal P50 suppression (Olincy &
Martin, 2005). Abnormalities in P50 suppression have
also been noted in FDRs of BD-I probands with psy-
chotic features (Schulze et al. 2007 ; Hall et al. 2008), and
in patients with SPD (Cadenhead et al. 2002).
Prepulse inhibition (PPI)
Patients with schizophrenia show a reduced inhibition
of the startle response by a prepulse stimulus (PPI),
even when the startle reﬂex is generally within the
normal range (Braﬀ et al. 2001). The deﬁcit is also
observed in non-psychotic patients, patients not on
medications (Swerdlow et al. 2006), and in FDRs who
are clinically unaﬀected (Kumari et al. 2005).
Similar to schizophrenic probands, impairment in
PPI has been consistently observed in BD during acute
episodes (Perry et al. 2001), and also in remitted pa-
tients (Quraishi & Frangou, 2002 ; Martinez-Aran
et al. 2004 ; Frangou et al. 2005 ; Robinson et al. 2006).
Three studies have noted PPI deﬁcits in unaﬀected
FDRs of BD probands (Zalla et al. 2004 ; Frangou
et al. 2005 ; Giakoumaki et al. 2007), suggesting that
PPI impairment may mark psychosis liability in both
schizophrenia and BD, and is associated with shared
genetic predisposition to psychotic symptoms. How-
ever, these deﬁcits also occur in disorders of other
clusters including co-morbid attention deﬁcit hyper-
activity disorder, tic disorders, obsessive–compul-
sive disorder, and Huntington’s disease (Braﬀ et al.
2001).
P300 evoked potential
BD and schizophrenia have reduced P300 amplitude
and increased latency (Souza et al. 1995 ; Ford, 1999).
This deﬁcit is heritable and probably related to the
etiology of the two diagnoses as similar impairments
are observed in FDRs of both disorder probands
(Pierson et al. 2000 ; Turetsky et al. 2000 ; van
Beijsterveldt et al. 2001 ; Winterer et al. 2003 ; Bramon
et al. 2005).
Early information processing and mismatch
negativity
Abnormalities in mismatch negativity are consistently
demonstrated in the auditory modality of schizo-
phrenic probands ; however, the ﬁndings in their un-
aﬀected relatives are less consistent (Michie et al. 2002;
Umbricht & Krljes, 2005 ; Magno et al. 2008). Although
not studied extensively, BD patients show unimpaired
mismatch negativity (Umbricht et al. 2003).
Neural synchronization deﬁcits
Studies have found abnormality in gamma (30–80 Hz)
synchronization in schizophrenia patients (Kwon
et al. 1999 ; Hong et al. 2004) and their FDRs. Similar
reductions in the gamma band synchronization are
also noted in BD (O’Donnell et al. 2004 ; Maharajh et al.
2007). The reduced synchrony in the gamma band
is correlated to positive symptom ratings such as vis-
ual hallucinations, thought disorder, conceptual dis-
organization, and attention in schizophrenia subjects
(O’Donnell et al. 2004 ; Hermann & Demiralp, 2005).
In summary, although there are extensive data on
biomarkers in schizophrenia probands and their rela-
tives, such information is meager in BD. Few studies
have directly compared biomarkers in schizophrenia
and BD families. The existing data suggest that many
of the biomarkers index independent aspects of psy-
chosis risk (Light & Braﬀ, 2001 ; Hong et al. 2007).
Measures of early sensory processing such as smooth
pursuit initiation, motion perception and mismatch
negativity seem to be unique to schizophrenia liability
and tend to be associated with negative symptoms
(Hong et al. 2003 ; Slaghuis et al. 2005 ; Urban et al.
2008), whereas abnormalities in smooth pursuit main-
tenance, sensory and sensory-motor gating, the P300
component of evoked potential and gamma-band syn-
chronization mark positive psychotic symptoms and
are present in both schizophrenia and BD. Table 2 pre-
sents a summary of neurophysiological marker ﬁnd-
ings.
Shared temperamental antecedents
A strong body of evidence originating in experimental
psychology supports the existence of polygenetically
inherited variations in temperament and personality
factors, which, if inherited in particular combinations,
may render an individual vulnerable to the develop-
ment of psychosis (Green et al. 2008). This view is
supported by large population-based evidence of the
existence of psychotic-like experiences in ostensibly
healthy individuals (van Os et al. 2000, 2009), and
considerable evidence of cognitive, perceptual and
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psychophysiological characteristics shared by indi-
viduals with psychotic disorders, their FDRs and psy-
chosis-prone individuals (Claridge, 1997).
The view that schizotypal characteristics could
represent both normal variation in personality and
vulnerability to clinical disorders has been diﬃcult to
reconcile with the psychiatric notion that these con-
ditions represent distinct classes of ‘ illness ’, separate
from normal function. Although it is beyond the scope
of this paper to fully review the evidence in support of
this notion, two recent papers have examined whether
psychotic-like experiences form a major domain of
human variation. Tackett et al. (2008) examined the
factor structure of a standard set of abnormal person-
ality scales that was augmented by the inclusion of
indices of schizotypal personality in a sample de-
signed to be weighted toward psychosis proneness
with the inclusion of FDRs of probands with schizo-
phrenia, schizo-aﬀective and BD diagnoses. Elements
of the four-factor structure of abnormal personality
that has been discussed extensively as a potential
dimensional model for abnormal personality in
DSM-V (Widiger et al. 2005) emerged, encompassing
domains of emotional dysregulation (neuroticism), in-
troversion, compulsivity and antagonism, augmented
by an additional ﬁfth dimension of ‘peculiarity ’, pri-
marily reﬂecting the inclusion of the schizotypy scales.
Watson et al. (2008) reported very similar results in a
sample of college students who completed a similarly
enriched set of indicators of abnormal personality.
Of course, the self-report personality indicators in
these studies do not constitute diagnosable psychotic
disorder per se, but at least some of these personality
indicators have shown predictive validity for psy-
chotic disorder diagnosed through structured inter-
views (Raine, 2006). Studies in this vein generally
support a spectrum relationship between schizo-
phrenia and schizotypal personality structure, refer-
ring not only to clinical presentation of SPD but also
to more broadly deﬁned ‘schizotypal ’ personality
characteristics within healthy individuals. Some qua-
lities of other cluster A personality disorders may also
relate to the peculiarity domain identiﬁed in recent
factor analytic studies, but the DSM-IV construct that
maps best onto this domain is clearly SPD. Endo-
phenotypes, described above as biomarkers, sub-
stantiates the relationship between schizophrenia and
relatives with schizophrenia spectrum pathology. The
relationship between personality and the various
other psychotic disorders such as brief reactive psy-
chosis or delusional disorder, has not been a major
focus of research.
Shared cognitive and emotional processing
abnormalities
Cognitive impairment
Cognitive impairments are consistently noted in
schizophrenia, BD, SPD (Green, 2006), and schizo-
aﬀective disorder (Stip et al. 2005 ; Torrent et al. 2007).
These deﬁcits are thought to underlie functional dis-
abilities (Bilder et al. 1991 ; Hill et al. 2004 ; Green, 2006),
and may represent candidate endophenotypes for
psychotic conditions that may span current diagnostic
groups (Arts et al. 2007 ; Glahn et al. 2007). Cognitive
Table 2. Summary of neurophysiological marker ﬁndings
Neurophysiological
marker
Schizophrenia/
relatives
Bipolar/
relatives Genetic ﬁndings Implicated neurotransmitter
1. SPEM
Predictive pursuit +++/++ +/+ 6p21, COMT
Pursuit initiation +/+ x/x Nicotine, NMDA
2. P50 ++/+ +/+ 15q14/CHRNA7 Nicotine, adrenergic, serotonergic
3. PPI ++/+ +/+ 22q11a, NR1 Dopamine, NMDA, Nicotine
4. P300 ++/+ +/+ 4q22b, 1q42c, DRD2,
DRD3, COMT
5. MMN ++/+ x/x NMDA
6. Neural synchronization ++/+ + GABA, NMDA
SPEM, Smooth pursuit eye movements ; PPI, prepulse inhibition ; MMN, mismatch negativity ; COMT, catecholamine-O-
methyltransferase gene ; CHRNA7, alpha 7 nicotinic cholinergic receptor gene ; NR1, neuregulin 1 gene ; DRD2 and DRD3,
dopamine receptor D2 and D3 genes ; NMDA, N-methyl-D-aspartic acid ; GABA, gamma-aminobutyric acid.
+, Some evidence ;++, some replications ;+++, repeatedly replicated ﬁnding.
a Based on ﬁndings in 22q11 deletion syndrome.
b Based on a study in alcoholism.
c Based on ﬁndings in (1 ;11) translocation carriers. Details and appropriate citations are given in the text.
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domains aﬀected in schizophrenia include deﬁcits in
sustained attention, visual and verbal episodic mem-
ory, working memory, and processing speed (Saykin
et al. 1991 ; Cannon et al. 2000 ; Green et al. 2000 ; Egan
et al. 2001 ; Dickinson et al. 2004). In general, the pattern
of cognitive deﬁcits in BD is similar to the cognitive
proﬁle of schizophrenia, although impairment may
be somewhat less severe and state dependent in BD
(Egan et al. 2001 ; Krabbendam et al. 2005 ; Arts et al.
2007). The FDRs of schizophrenia patients show
similar cognitive deﬁcits ; although the abnormalities
are less salient, this ﬁnding supports the heritability
of these deﬁcits (Snitz et al. 2006). Some of the
available data, in relatively small samples, suggest
that cognitive deﬁcits observed in the BD probands
also occur in their FDRs (Antila et al. 2007; Trivedi et al.
2008).
In general, cognitive deﬁcits in all domains begin
before psychosis and remain stable over the course of
schizophrenia (Rund, 1998), whereas deﬁcits in atten-
tion and executive function seem to be most stable in
BD (Burdick et al. 2006 ; Mur et al. 2008). However,
ﬂuctuating attentional disturbances have been re-
ported in schizophrenia (Dawson et al. 1994). Cogni-
tive impairments in BD tend to vary signiﬁcantly with
clinical state and deteriorate as the illness progresses
(Burt et al. 2000). However, subtle impairments in
executive function, verbal ﬂuency, attention and
episodic memory are observed in BD relatives and
patients even during euthymic phases (Deckersbach
et al. 2004 ; Malhi et al. 2004 ; Pavuluri et al. 2006, 2008 ;
Bora et al. 2008). Comparison of cognitive deﬁcits in
BD-I and BD-II revealed more severe deﬁcits in BD-I,
consistent with a functional distinction between these
groups (Simonsen et al. 2008).
Emotion
Patients with schizophrenia often demonstrate a re-
stricted emotional range and diminished ability to
experience pleasure (anhedonia) (see, for example,
Bleuler, 1911 ; Kraepelin, 1917 ; Carpenter et al. 1988).
Anhedonia correlates signiﬁcantly with other negative
symptoms of schizophrenia such as aﬀective ﬂatten-
ing, avolitional pathology including asociality, apathy,
alogia, and is independent of positive symptoms and
disorganization (Blanchard & Cohen, 2006). Anhe-
donia has been thought to be a marker of a genetic
liability to schizophrenia (Chapman et al. 1976 ; Glatt
et al. 2006) and may be associated with anhedonia in
the general population (Tomppo et al. 2009). By con-
trast, restricted emotional range and anergia are not
commonly associated with BD except when secondary
to depression. Anhedonia is not a liability marker for
BD (Katsanis et al. 1992; Etain et al. 2007).
Symptom similarity
The symptom commonality across the disorders in
DSM-IV-TR schizophrenia and related psychoses is
based on reality distortion (i.e. hallucinations and
delusions). Other criteria A symptoms for schizo-
phrenia are used to diﬀerentiate this diagnosis from
other psychotic disorders (e.g. disorganization, nega-
tive symptoms, psychomotor abnormalities). Reality
distortion is associated with many disorders and
is not decisive for etiologically based classiﬁcations.
Bleuler (1911) considered hallucinations and delusions
as secondary manifestations and Kraepelin (1917)
viewed the combination of avolition and dissociative
thought, and the diﬀerence between chronic course and
episodic course as the deﬁning clinical features that
separated dementia praecox from manic-depressive
disorder. Schneiderian ﬁrst-rank symptoms are, how-
ever, reality distortion phenomena. DSM-IV-TR cri-
teria for schizophrenia can be met by hallucinations
and delusions alone, or even just delusions, if bizarre.
What is the aﬃnity of SPD and BD in light of a tra-
ditional view of schizophrenia or the current DSM
emphasis on reality distortion?
The answer for SPD is clear at a deﬁnitional level. If
magical ideation and perceptual aberrations reach
psychotic severity, the case meets criteria for a psy-
chotic diagnosis. Nonetheless, there is a phenomeno-
logical similarity where schizotypal pathology can be
viewed on a continuum with psychosis, and simi-
larities reviewed above in other spectrum criteria sup-
port a close relationship to schizophrenia.
Comparing psychopathology of BD and schizo-
phrenia supports separateness. Much of the manifest
pathology of BD is mood disturbance, often with an
episodic pattern. Reality distortion may not occur in
BD-II, and is often not present during episodes of BD-
I. First-rank symptoms occur in both, but more fre-
quently in schizophrenia. Bizarre reality distortion
experiences (Jaspers, 1962) in schizophrenia contrast
with the mood-congruent delusions in BD. Thought
disturbance is present in both syndromes, but is quite
diﬀerent. Excessive, grandiose and pressured thought
and speech is typical in one syndrome whereas dis-
organized speech with impoverished content is ob-
served in the other. Although depressed aﬀect is
present in many cases of schizophrenia, other cases
have restricted aﬀect. Excessive aﬀect is typical of BD
except in some chronic cases. Avolition deﬁnes at
least a subtype of schizophrenia and is not associated
with BD (Kirkpatrick et al. 2001 ; Fischer & Carpenter,
2009).
In summary, SPD is separated from the psychoses
group by deﬁnition although manifestations can be
viewed as a mild version of schizophrenia. However,
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BD and schizophrenia are diﬀerentiated on a sympto-
matic basis.
High rates of co-morbidity among disorders as
currently deﬁned
Co-morbidity regarding domains of psychopathology
is extensive. Depressive, obsessive, anxiety, attention,
social, motor, suicidal, sleep disturbance and other
psychopathologies are frequently observed in patients
with diagnoses in the psychoses cluster. Overlap with
many other disorders (van Os et al. 2000) does not
suggest joining the various diagnostic categories in
the same grouping. A more meaningful question is
whether schizophrenia and other psychotic disorders
are co-morbid separate disease entities such as dia-
betes. Schizophrenia and BD are associated with high
prevalence of substance abuse, but this is true of many
disorders. Schizophrenia is co-morbid with aspects
of the metabolic syndrome including diabetes, but this
may relate to lifestyle rather than shared pathology.
Co-morbidity at the symptom level can be created by
deﬁnition as exempliﬁed by the diagnostic category of
schizo-aﬀective disorder (Malhi et al. 2008).
Course of illness
Schizophrenia does not have a ‘ typical ’ course
(Carpenter & Kirkpatrick 1988; Harding 1988), and the
course pattern is variable for BD. Recurrent episodes
in schizophrenia tend to be manifestations of symp-
toms observed previously whereas BD may have dis-
tinctive presentations at opposite ends of an aﬀect
continuum across episodes. However, more patients
with schizophrenia than BD have continuous, rather
than phasic, courses. It should be noted that this dis-
tinction is based on a proportion of cases rather
than unique disorder patterns, and good prognosis
cases are often under-represented in long-term course
studies.
Both BD aﬀect disturbance and schizophrenia psy-
chosis have typical age–incidence curves with onset in
young people (Kennedy et al. 2005b) and both display
earlier onset in men (Kennedy et al. 2005a). However,
core schizophrenia pathologies (e.g. negative symp-
toms and cognitive impairment) begin much earlier in
most cases. Schizophrenia is associated with a decline
in cognition during developmental years and trait-like
stability of impairments over time (Woodberry et al.
2008). BD is not generally associated with develop-
mental impairment, prompting the suggestion that the
major diﬀerence between the two conditions is that
schizophrenia, but not BD, is developmental in origin
(Murray et al. 2004). The distinct longitudinal patterns
of schizophrenia and BD separated the disorders in
the original Kraepelinian concept, but heterogeneity in
course is present in each syndrome.
Avolitional pathology begins early and aﬄicts
a minority of cases of schizophrenia. This pathology
is rare in the pre-onset and early course of BD. This
schizophrenia subgroup is substantially diﬀerent from
BD, but is also distinguished from other schizophrenia
subgroups (Kirkpatrick et al. 2001).
Treatment response
All antipsychotic drugs reduce the experience of psy-
chosis, regardless of diagnostic category, and may re-
duce relapse rates. All share a mechanism of action
at the dopamine D2 receptor. By contrast, lithium has
therapeutic and prophylactic eﬀects for depression
and mania in BD patients but is not documented as
eﬀective in schizophrenia patients. One study that did
examine the eﬀects of lithium in schizophrenia pa-
tients found that eﬀects were only evident on mood
(Johnstone et al. 1988). Antidepressant drugs have ef-
ﬁcacy in BD, but eﬃcacy has not been established in
schizophrenia. Although controversial, there are data
suggesting that antidepressant drugs may trigger
mania in BD but may decrease psychotic relapse in
schizophrenia (Siris et al. 1994 ; Ghaemi et al. 2003). In
general, psychopharmacology eﬀects suggest sub-
stantial diﬀerences in treatment response except with
antipsychotic drugs. The latter are not diagnostically
speciﬁc.
Conclusions
The primary argument for grouping several disorders
in a psychosis cluster is shared reality testing patho-
logy and the absence of a compelling case for location
elsewhere (e.g. psychosis with Alzheimer’s disease).
We propose keeping this grouping, incorporating the
psychotic disorders already clustered in DSM-IV-TR.
There are few data testing the ﬁt between these dis-
orders on the 11 criteria except for similarity in reality
distortion symptom criteria. The more challenging is-
sue involves grouping SPD and BDwith the psychoses
cluster.
The question of adding SPD is cogent because
compelling similarities in many of the 11 validating
criteria are documented. The main reservation relates
to failure of cases to manifest psychotic symptoms
and the fact that antipsychotic drugs are not front-
line therapy. If psychosis emerges, the diagnosis is
changed. A decision on this for DSM-V must also con-
sider how personality disorders are conceptualized.
More complicated is the question of BD. There is
substantial overlap in neural substrate, biomarkers,
genetic and environmental eﬀects, cognition, and
Cluster 3 : psychoses 2033
aspects of symptoms, treatment and course. Yet, in
each of these areas there are data supporting unique
features. There is no consensus on whether any of
the data reviewed above are decisive for validation
of cluster membership. An additional consideration
involves comparing BD with other mood disorders
on the 11 proposed criteria (Goldberg et al. 2009a).
Similarities between BD and schizophrenia are exten-
sively based on BD-I with psychosis. It is likely that
BD-II will overlap extensively with mood disorders,
and the question of splitting BD-I and BD-II will have
to be addressed. There may be insuﬃcient evidence to
de-link these two forms of BD at present. The fact that
many BD patients never manifest psychosis argues
against BD joining the psychosis chapter, as does the
substantial diﬀerence in phenomenology.
Grouping BD and SPD with the current psychoses
group could facilitate the identiﬁcation of shared
mechanisms of pathophysiology. The cluster could fa-
cilitate investigative focus on crucial issues that dis-
tinguish between classes within the cluster and that
deﬁne the porous boundaries across current classes.
This process will be facilitated by DSM-V if key di-
mensions of pathology associated with the grouping
are identiﬁed and the paradigm for etiological in-
vestigations shifts from diagnostic class/syndrome to
pathological dimension (Strauss et al. 1974 ; Carpenter
& Buchanan, 1989) or endophenotypes (Gottesman &
Gould, 2003).
There are several limitations in proposing the psy-
choses cluster based on the 11 spectrum criteria. Five
caveats require attention. First, there is insuﬃcient
evidence on the etiology and pathophysiology to base
group membership on causality. Second, the ultimate
determination of group membership for disorders at
the border of proposed clusters requires examination
of similarities and diﬀerences with both clusters.
Third, in-depth phenomenology and pattern of illness
are not examined in most studies, and state versus trait
issues may be crucial. Fourth, psychosis is the main
deﬁning feature for grouping these disorders. An
alternative is to regard psychosis, especially reality
distortion symptoms, as a common manifestation of
many disorders and not rare in the general population.
Fifth, it is not known whether the 11 spectrum criteria
would support the DSM-IV cluster of schizophrenia
and related disorders. Groupings would be very dif-
ferent if deﬁned by other trait pathologies of schizo-
phrenia such as avolitional pathology. In summary,
the proposed move of BD-I and BD-II from a mood
cluster to a psychosis cluster receives only modest
support from data relating to the 11 spectrum criteria.
This support may be insuﬃcient to overcome tradition
and the substantial symptomatic and therapeutic
diﬀerences with schizophrenia. There is substantial
support for SPD, but psychosis as a deﬁning feature
may preclude inclusion of a personality disorder in the
psychosis cluster.
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